PURAPHARM (01498) announced that, in accordance with the patent license agreement dated July 25, 2025, the company allotted and issued 93.4884 million consideration shares on October 30, 2025. Additionally, under the subscription agreement dated July 25, 2025, the company allotted and issued 46.512 million subscription shares on the same date.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.